The week in pharma: action, reaction and insight – week to June 10, 2022

By Barbara Obstoj-Cardwell. Editor

Last week’s news saw a lot of Save coverage of the American Society of Clinical Oncology (ASCO) meeting, among which the presentation of Phase III data on Enhertu by AstraZeneca and Daiichi Sankyo was viewed as especially important. Almirall and partner Eli Lilly on Tuesday released impressive new data on their lebrikizumab in the treatment of dermatitis. US Food and Drug Administration advisory committee meetings also attracted a good deal of attention. First, an AdCom voted overwhelmingly for the grant of emergency use authorization of Novavax’ COVID-19 vaccine Nuvaxovid. Thursday and Friday saw consecutive positive outcomes for bluebird bio’s gene therapies, first for its elivaldogene autotemcel (eli-cel) and then for beta-thalassemia candidate betibeglogene autotemcel (beti-cel).

Standing ovation for Enhertu in HER2-low mBC at ASCO